236 related articles for article (PubMed ID: 17320674)
21. Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.
Prada PJ; Anchuelo J; Blanco AG; Paya G; Cardenal J; Acuna E; Ferri M; Vazquez A; Pacheco M; Sanchez J
Int Braz J Urol; 2016; 42(1):47-52. PubMed ID: 27136466
[TBL] [Abstract][Full Text] [Related]
22. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy.
Whaley JT; Levy LB; Swanson DA; Pugh TJ; Kudchadker RJ; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e765-71. PubMed ID: 22300559
[TBL] [Abstract][Full Text] [Related]
23. Erectile function after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
[TBL] [Abstract][Full Text] [Related]
24. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
25. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
[TBL] [Abstract][Full Text] [Related]
26. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
Solan AN; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1468-74. PubMed ID: 18922652
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
29. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
Brown D; Colonias A; Miller R; Benoit R; Cohen J; Arshoun Y; Galloway M; Karlovits S; Wu A; Johnson M; Quinn A; Kalnicki S
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):353-60. PubMed ID: 10802359
[TBL] [Abstract][Full Text] [Related]
30. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
31. 125I brachytherapy for localized prostate cancer: a single institution experience.
Guarneri A; Botticella A; Filippi AR; Munoz F; Beltramo G; Casetta G; Giglioli FR; Tizzani A; Ragona R; Ricardi U
Tumori; 2013; 99(1):83-7. PubMed ID: 23549005
[TBL] [Abstract][Full Text] [Related]
32. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
33. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH
Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933
[TBL] [Abstract][Full Text] [Related]
34. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
36. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
37. [Prostate I-125 brachytherapy: critical evaluation of mid-term oncologic and functional results in 250 cases].
Gastaldi E; Chiono L; Gallo F; Giberti C
Urologia; 2011; 78(2):86-91. PubMed ID: 21574147
[TBL] [Abstract][Full Text] [Related]
38. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
[TBL] [Abstract][Full Text] [Related]
39. Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
Kikkawa K; Iba A; Kohjimoto Y; Noda Y; Sonomura T; Hara I
Int J Urol; 2018 Apr; 25(4):366-371. PubMed ID: 29397569
[TBL] [Abstract][Full Text] [Related]
40. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
